---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-048772"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2021-09-24T23:59:59+00:00"
generated_at: "2026-06-29T01:40:18.601039+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics appoints two new independent directors to board

## Summary
- Sharmila Dissanaike, M.D. appointed to board effective Sept 20, 2021; she is a trauma surgeon and University Distinguished Professor at Texas Tech.
- Susan Rodriguez appointed to board effective same date; she is Chief Commercial Officer of Ardelyx and has 25+ years biopharma experience.
- Both directors will serve initial term until 2022 Annual Meeting; initial equity awards: 37,500 options and 6,250 RSUs each.
- Both qualify as independent under Nasdaq rules; not immediately assigned to any Board committees.

## SEC filing metadata
- accession: 0001564590-21-048772
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2021-09-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000156459021048772/0001564590-21-048772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000156459021048772/hrtx-8k_20210920.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-048772
- JSON: https://secwatch.observer/filing/0001564590-21-048772.json
- Plain text: https://secwatch.observer/filing/0001564590-21-048772.txt

## Key facts
- Executive change
  Susan Rodriguez was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
  - Action: appointed
  - Role: Director
  source text: Effective as of September 20, 2021, the Board appointed Susan Rodriguez to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000156459021048772/0001564590-21-048772-index.htm
- Executive change
  Sharmila Dissanaike was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
  - Action: appointed
  - Role: Director
  source text: Effective as of September 20, 2021, the Board of Directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”) appointed Sharmila Dissanaike, M.D. to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000156459021048772/0001564590-21-048772-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.